Literature DB >> 12580337

Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems.

Fu-Ming Zhou1, Charles Wilson, John A Dani.   

Abstract

The striatum and its dense dopaminergic innervation originating in the midbrain, primarily from the substantia nigra pars compacta and the ventral tegmental area, compose the mesostriatal dopamine (DA) systems. The nigrostriatal system is involved mainly in motor coordination and in disorders such as Tourette's syndrome, Huntington's disease, and Parkinson's disease. The dopaminergic projections from the ventral tegmental area to the striatum participate more in the processes that shape behaviors leading to reward, and addictive drugs act upon this mesolimbic system. The midbrain DA areas receive cholinergic innervation from the pedunculopontine tegmentum and the laterodorsal pontine tegmentum, whereas the striatum receives dense cholinergic innervation from local interneurons. The various neurons of the mesostriatal systems express multiple types of muscarinic and nicotinic acetylcholine receptors as well as DA receptors. Especially in the striatum, the dense mingling of dopaminergic and cholinergic constituents enables potent interactions. Evidence indicates that cholinergic and dopaminergic systems work together to produce the coordinated functioning of the striatum. Loss of that cooperative activity contributes to the dysfunction underlying Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12580337     DOI: 10.1177/1073858402239588

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  52 in total

1.  Dopaminergic reward system: a short integrative review.

Authors:  Oscar Arias-Carrión; Maria Stamelou; Eric Murillo-Rodríguez; Manuel Menéndez-González; Ernst Pöppel
Journal:  Int Arch Med       Date:  2010-10-06

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.

Authors:  R Ceravolo; D Volterrani; D Frosini; S Bernardini; C Rossi; C Logi; G Manca; L Kiferle; G Mariani; L Murri; U Bonuccelli
Journal:  J Neural Transm (Vienna)       Date:  2006-06-14       Impact factor: 3.575

4.  Cholinergic interneurons control the excitatory input to the striatum.

Authors:  Pavel Pakhotin; Enrico Bracci
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

Review 5.  Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission.

Authors:  R Exley; S J Cragg
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

6.  Dopaminergic and cholinergic modulation of striatal tyrosine hydroxylase interneurons.

Authors:  Osvaldo Ibáñez-Sandoval; Harry S Xenias; James M Tepper; Tibor Koós
Journal:  Neuropharmacology       Date:  2015-04-20       Impact factor: 5.250

Review 7.  Striatal action-learning based on dopamine concentration.

Authors:  Genela Morris; Robert Schmidt; Hagai Bergman
Journal:  Exp Brain Res       Date:  2009-11-11       Impact factor: 1.972

Review 8.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

9.  Thalamic gating of corticostriatal signaling by cholinergic interneurons.

Authors:  Jun B Ding; Jaime N Guzman; Jayms D Peterson; Joshua A Goldberg; D James Surmeier
Journal:  Neuron       Date:  2010-07-29       Impact factor: 17.173

10.  Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens.

Authors:  Pedro Rada; Jessica R Barson; Sarah F Leibowitz; Bartley G Hoebel
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.